Elizabeth Crowley compensation by year
Celldex Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $321,970 | $337,302 | $343,330 | $350,484 | $365,662 | $446,905 | $473,883 |
| Bonus | $97,000 | $105,000 | $107,000 | $104,000 | $138,250 | $234,000 | $260,000 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $255,182 | $127,617 | $130,834 | $89,689 | $668,842 | $2,239,410 | $1,141,151 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $4,233 | $4,481 | $4,544 | $3,481 | $3,324 | $10,033 | $10,175 |
| Total | $678,385 | $574,400 | $585,708 | $547,654 | $1,176,078 | $2,930,348 | $1,885,209 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Celldex Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-050884, and prior-year filings.
How this page was built: the Celldex Therapeutics, Inc. filed document, accession 0001104659-26-050884. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 9,625 | — | $22.48 |
| Option | 53,125 | — | $36.43 |
| Option | 85,000 | — | $19.53 |
| Option | 30,000 | — | $36.87 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Celldex Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 29, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-25 | Grant or award derivative | — | 100,000 | $0.00 | 100,000 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Celldex Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
| Resignation for good reason, no change in control | $498,000 | $173,399 | $0 | $671,399 |
| Involuntary termination without cause | $498,000 | $173,399 | $0 | $671,399 |
| Change in control and involuntary termination | $996,000 | $693,595 | $0 | $2,079,595 |
Per the Potential Payments Upon Termination or Change in Control table in Celldex Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Celldex Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Anthony Marucci | President, Chief Executive Officer and Director | $5,366,709 |
| Tibor Keler | Executive Vice President and Chief Scientific Officer | $2,115,717 |
| Elizabeth Crowley · this page | Senior Vice President, Chief Product Development Officer | $1,885,209 |
| Sam Martin | Senior Vice President, Chief Financial Officer and Secretary | $1,827,112 |
| Margo Heath-Chiozzi | Senior Vice President, Regulatory Affairs | $1,820,359 |
The full Celldex Therapeutics compensation record
free company briefThis page is one person within Celldex Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Celldex Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Celldex Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Celldex Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.